TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05583149
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
Study: NCT01410708
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05004129
Drug: Tideglusib
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
Study: NCT05035589
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
Study: NCT05681429
Drug: Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
Study: NCT05266404
Drug: Dapagliflozin/sitagliptin FDC
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
Study: NCT03620318
Drug: Crenolanib besylate
Normalized name: mesylate
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05369481
Drug: Sildenafil 2%
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
Study: NCT05369481
Drug: Minoxidil 5 %
Normalized name: minoxidil 5 % TOPICAL KIT
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
Study: NCT05266404
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive 100 mg single dose of Sitagliptin orally.
Study: NCT05266404
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive 10 mg single dose of Dapagliflozin orally.
Study: NCT05682859
Drug: Roflumilast 500 Mcg Oral Tablet
Normalized name: roflumilast 500 mcg oral tablet
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
Study: NCT06497296
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
Study: NCT04648930
Drug: Xolair
Normalized name: Xolair
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT00029757
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05556122
Drug: ropivacaine + compound betamethasone
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
Study: NCT05518708
Drug: BI 3032950
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 3032950
Study: NCT05792527
Drug: L-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 500 mg tablet twice daily after meals
Study: NCT05251038
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intervention instruction outlined in protocol
Study: NCT05251038
Drug: Liposomal Irinotecan (nal-IRI)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention instruction outlined in protocol
Study: NCT05251038
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per standard of care
Study: NCT05251038
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per standard of care
Study: NCT05345210
Drug: Vonoprazan Fumarate+Amoxycillin 14days (VA14)
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study: NCT05345210
Drug: Vonoprazan Fumarate+Amoxycillin 7days (VA7)
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study: NCT05562349
Drug: Clavulanic Acid Only Product
Normalized name: Clavulanic acid only product
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be given in 250mg capsules
Study: NCT05696574
Drug: Vaginal Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
Study: NCT05696574
Drug: Oral Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
Study: NCT05329116
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
Study: NCT04774159
Drug: Colchicine 0.5 MG Oral Tablet
Normalized name: colchicine 0.5 mg oral tablet
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label.
Study: NCT04774159
Drug: Colchicine-Placebo
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine-Placebo tablet
Study: NCT06130722
Drug: FL115
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
Study: NCT06213662
Drug: Botulinum toxin type A for injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study: NCT05822050
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: XPO1 inhibitor
Study: NCT00799539
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
Study: NCT00799539
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
Study: NCT00799539
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
Study: NCT00799539
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
Study: NCT05496725
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetic study under fasting conditions
Study: NCT00967759
Drug: Bronpheniramine and fenilefrine (Decongex Plus)
Normalized name: cytarabine and daunorubicin
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Study: NCT00967759
Drug: Bronpheniramine isolated
Normalized name: ISOLATE
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Study: NCT05693454
Drug: Infiltration with NaCl
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local wound infiltration at the end of spine surgery with NaCl
Study: NCT05693454
Drug: Infiltration with a combination of Levobupivacaine and Tramadol
Normalized name: combinations of levothyroxine and liothyronine
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
Study: NCT04733157
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
Study: NCT05269030
Drug: Ivermectin Topical
Normalized name: Ivermectin Topical
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 1% in a dose of two drops per nostril twice daily.
Study: NCT05269030
Drug: Budesonide Nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily.
Study: NCT06172400
Drug: Mepivacaine, Combinations
Normalized name: mepivacaine, combinations
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
Study: NCT02459392
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration
Study: NCT02459392
Drug: DepoMedrol
Normalized name: epomediol
DrugBank: Epomediol (DB13802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administration
Study: NCT06467526
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hydroxychloroquine (400mg/day) for 2 months
Study: NCT06182267
Drug: Sodium Fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toothpaste
Study: NCT05379959
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given 125 mg of MDMA.
Study: NCT05379959
Drug: Methamphetamine
Normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given 20 mg of MA.
Study: NCT00002393
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002393
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06505486
Drug: Gemcitabine-Oxaliplatin Regimen
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
Study: NCT05732883
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection
Study: NCT05845125
Drug: Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint.
Study: NCT06438796
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
Study: NCT04778800
Drug: almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
Study: NCT04607122
Drug: Landiolol
Normalized name: Landiolol
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
Study: NCT04607122
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of saline solution at the same rate as landiolol infusion.
Study: NCT06302257
Drug: Chlorprocaine
Normalized name: Chlorprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
Study: NCT06302257
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will receive lidocaine alone
Study: NCT06302257
Drug: Lidocaine-chlorprocaine combination
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
Study: NCT06547957
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of EOS301984 in combination with Anti-PD-1
Study: NCT05943080
Drug: PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
Study: NCT05943080
Drug: ACB ( 0.25% marcaine + %0.9 saline)
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
Study: NCT04820751
Drug: Cyproheptadine Hydrochloride 4 MG
Normalized name: cyproheptadine hydrochloride 4 MG
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine associated to standard care
Study: NCT00215865
Drug: PEGIntron plus ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06573190
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Therapy
Study: NCT06573021
Drug: Near-infrared fluorescent cholangiography
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
Study: NCT05491759
Drug: Product 1 - AquaCelle Fish Oil Triglyceride
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
Study: NCT05491759
Drug: Product 2 - AquaCelle Fish Oil Ethyl Ester
Normalized name: 2-oxopropanoic acid ethyl ester
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
Study: NCT05491759
Drug: Product 3 - Standard Fish Oil Triglyceride
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
Study: NCT05956418
Drug: Centhaquine
Normalized name: Centhaquine
DrugBank: Centhaquine (DB16122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
Study: NCT06381830
Drug: CAR-T Cell Therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
Study: NCT05069012
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
Study: NCT06243120
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
Study: NCT00000652
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000652
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06102772
Drug: Adebrelimab，Fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab，Fruquintinib combined with chemotherapy
Study: NCT05478174
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for induction of general anesthesia.
Study: NCT06109948
Drug: ABX1100 injection for IV infusion
Normalized name: ABX1100
DrugBank: ABX1100 (DB17655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centyrin protein-siRNA conjugate